Initial Safety and Efficacy of Dose-Escalating HDACs Inhibitor Chidamide with VRD (Chi-VRD) Treatment for Newly-Diagnosed High-Risk Transplant Eligible Multiple Myeloma Patients
Sign Up to like & getrecommendations! Published in 2019 at "Blood"
DOI: 10.1182/blood-2019-129434
Abstract: Background Deregulation of histone acetylation has been recognized to serve a critical role in the pathogenesis of multiple myeloma (MM), which histone deacetylase (HDACs) are overexpressed in plasma cells derived from patients with MM. Therefore,… read more here.
Keywords: chidamide; risk; high risk; treatment ... See more keywords